Immunological mechanisms of the antitumor effects of supplemental oxygenation

Science Translational Medicine

Volumn 7, Issue 277, 2015, Pages

  Hatfield, Stephen M ^a   Kjaergaard, Jorgen ^a   Lukashev, Dmitriy ^a   Schreiber, Taylor H ^b,f   Belikoff, Bryan ^a   Abbott, Robert ^a   Sethumadhavan, Shalini ^a   Philbrook, Phaethon ^a   Ko, Kami ^a   Cannici, Ryan ^a   Thayer, Molly ^a   Rodig, Scott ^c   Kutok, Jeffrey L ^c,g   Jackson, Edwin K ^d   Karger, Barry ^a   Podack, Eckhard R ^b   Ohta, Akio ^a   Sitkovsky, Michail V ^a,e  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e HARVARD INSTITUTES OF MEDICINE   (United States)

^f Heat Biologics Inc   (United States)

^g Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACETYLCYSTEINE; ADENOSINE A2 RECEPTOR; CARBOGEN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD39 ANTIGEN; CD69 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HERMES ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; OXYGEN; PROGRAMMED DEATH 1 RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; ADENOSINE; ANTINEOPLASTIC AGENT;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; BREATHING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HYPEROXIA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LUNG TUMOR; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHOTODYNAMICS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; HYPOXIA; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; REMISSION; TUMOR CELL LINE;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPEROXIA; HYPOXIA; IMMUNOSUPPRESSION; KILLER CELLS, NATURAL; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; OXYGEN; REMISSION INDUCTION; RESPIRATION; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84929008590     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa1260     Document Type: Article

References (49)

1. A. Ohta, M. Sitkovsky, Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916-920 (2001).
2. A. Ohta, E. Gorelik, S. J. Prasad, F. Ronchese, D. Lukashev, M. K. K. Wong, X. Huang, S. Caldwell, K. Liu, P. Smith, J.-F. Chen, E. K. Jackson, S. Apasov, S. Abrams, M. Sitkovsky, A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. U.S.A. 103, 13132-13137 (2006).
3. H. K. Eltzschig, M. V. Sitkovsky, S. C. Robson, Purinergic signaling during inflammation. N. Engl. J. Med. 367, 2322-2333 (2012).
4. s protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J. Immunol. 175, 4383-4391 (2005).
5. M. V. Sitkovsky, T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol. 30, 102-108 (2009).
6. M. V. Sitkovsky, S. Hatfield, R. Abbott, B. Belikoff, D. Lukashev, A. Ohta, Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2, 598-605 (2014).
7. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, M. E. Dudley, Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008).
8. P. Sharma, K. Wagner, J. D. Wolchok, J. P. Allison, Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer 11, 805-812 (2011).
9. J. Naidoo, D. B. Page, J. D. Wolchok, Immune modulation for cancer therapy. Br. J. Cancer 111, 2214-2219 (2014).
10. I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
11. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
12. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
13. A. Young, D. Mittal, J. Stagg, M. J. Smyth, Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov. 4, 879-888 (2014).
14. C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, R. D. Schreiber, Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007).
15. 2A adenosine receptor. Cancer Immunol. Immunother. 61, 917-926 (2012).
16. B. M. Künzli, M. I. Bernlochner, S. Rath, S. Käser, E. Csizmadia, K. Enjyoji, P. Cowan, A. d'Apice, K. Dwyer, R. Rosenberg, A. Perren, H. Friess, C. A. Maurer, S. C. Robson, Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal. 7, 231-241 (2011).
17. J. Stagg, U. Divisekera, N. McLaughlin, J. Sharkey, S. Pommey, D. Denoyer, K. M. Dwyer, and M. J. Smyth, Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 107, 1547-1552 (2010).
18. J. Stagg, U. Divisekera, H. Duret, T. Sparwasser, M. W. L. Teng, P. K. Darcy, M. J. Smyth, CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892-2900 (2011).
19. D. Jin, J. Fan, L. Wang, L. F. Thompson, A. Liu, B. J. Daniel, T. Shin, T. J. Curiel, B. Zhang, CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245-2255 (2010).
20. + tumors. Proc. Natl. Acad. Sci. U.S.A. 110, 14711-14716 (2013).
21. S. Loi, S. Pommey, B. Haibe-Kains, P. A. Beavis, P. K. Darcy, M. J. Smyth, J. Stagg, CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 11091-11096 (2013).
22. R. H. Kallet, M. A. Matthay, Hyperoxic acute lung injury. Respir. Care 58, 123-141 (2013).
23. M. Thiel, A. Chouker, A. Ohta, E. Jackson, C Caldwell, P. Smith, D. Lukashev, I. Bittmann, M. V. Sitkovsky, Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLOS Biol. 3, e174 (2005).
24. P. Vaupel, Tumor oxygenation: An appraisal of past and present concepts and a look into the future: Arisztid G. B. Kovách Lecture. Adv. Exp. Med. Biol. 789, 229-236 (2013).
25. S. M. Hatfield, J. Kjaergaard, D. Lukashev, B. Belikoff, T. H. Schreiber, S. Sethumadhavan, R. Abbott, P. Philbrook, M. Thayer, D. Shujia, S. Rodig, J. L. Kutok, J. Ren, A. Ohta, E. R. Podack, B. Karger, E. K. Jackson, M. Sitkovsky, Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1a-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. 92, 1283-1292 (2014).
26. M. W. Dewhirst, Y. Cao, B. Moeller, Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8, 425-437 (2008).
27. J. Wang, J. Yi, Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol. Ther. 7, 1875-1884 (2008).
28. J. H. Min, C. N. Codipilly, S. Nasim, E. J. Miller, M. N. Ahmed, Synergistic protection against hyperoxia-induced lung injury by neutrophils blockade and EC-SOD overexpression. Respir. Res. 13, 58 (2012).
29. E. Kratzer, Y. Tian, N. Sarich, T. Wu, A. Meliton, A. Leff, A. A. Birukova, Oxidative stress contributes to lung injury and barrier dysfunction via microtubule destabilization. Am. J. Respir. Cell Mol. Biol. 47, 688-697 (2012).
30. J. Kjaergaard, S. Shu, Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J. Immunol. 163, 751-759 (1999).
31. J. Kjaergaard, L. Peng, P. A. Cohen, S. Shu, Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin. Immunol. 108, 8-20 (2003).
32. M. Champsaur, L. L. Lanier, Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267-285 (2010).
33. D. H. Raulet, S. Gasser, B. G. Gowen, W. Deng, H. Jung, Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413-441 (2013).
34. S. A. Quezada, K. S. Peggs, T. R. Simpson, Y. Shen, D. R. Littman, J. P. Allison, Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008).
35. T. H. Schreiber, V. V. Deyev, J. D. Rosenblatt, E. R. Podack, Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69, 2026-2033 (2009).
36. M. V. Sitkovsky, J. Kjaergaard, D. Lukashev, A. Ohta, Hypoxia-adenosinergic immunosuppression: Tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 14, 5947-5952 (2008).
37. + regulatory T cell function. Science 322, 271-275 (2008).
38. J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, S. Shu, Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167, 6669-6677 (2001).
39. M. Koshiba, H. Kojima, S. Huang, S. Apasov, M.V. Sitkovsky, Memory of extracellular adenosine A#INF#2#/INF#A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272, 25881-25889 (1997).
40. S. Kobayashi, H. Zimmermann, D. E. Millhorn, Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J. Neurochem. 74, 621-632 (2000).
41. U. K. Decking, G. Schlieper, K. Kroll, J. Schrader, Hypoxia-induced inhibition of adenosine-kinase potentiates cardiac adenosine release. Circ. Res. 81, 154-164 (1997).
42. K. Synnestvedt, G. T. Furuta, K. M. Comerford, N. Louis, J. Karhausen, H. K. Eltzschig, K. R. Hansen, L. F. Thompson, S. P. Colgan, Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993-1002 (2002).
43. C. A. Corzo, T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, T. V. McCaffrey, J. C McCaffrey, D. I. Gabrilovich, HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453 (2010).
44. O. R. Colegio, N.-Q. Chu, A. L Szabo, T. Chu, A. Marie Rhebergen, V. Jairam, N. Cyrus, C E. Brokowski, S. C. Eisenbarth, G. M. Phillips, G. W. Cline, A. J. Phillips, R. Medzhitov, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559-563 (2014).
45. P. Chaturvedi, D. M. Gilkes, N. Takano, G. L. Semenza, Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc. Natl. Acad. Sci. U.S.A. 111, E2120-E2129 (2014).
46. A. Ohta, M. Sitkovsky, Caveats in promising therapeutic targeting of the anti-inflammatory A2 adenosine receptors: The notes of caution. Nat. Rev. Drug Discov. 5 (2006).
47. H. Ooi, E. Cadogan, M. Sweeney, K. Howell, R. G. O'Regan, P. McLoughlin, Chronic hyper-capnia inhibits hypoxic pulmonary vascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 278, H331-H338 (2000).
48. H. R. De Smet, A. D. Bersten, H. A. Barr, I. R. Doyle, Hypercapnic acidosis modulates inflammation, lung mechanics, and edema in the isolated perfused lung. J. Crit. Care 22, 305-313 (2007).
49. J. Kjaergaard, J. Tanaka, J. A. Kim, K. Rothchild, A. Weinberg, S. Shu, Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60, 5514-5521 (2000).